APM
Avidity Partners Management Portfolio holdings
AUM
$499M
This Quarter Return
+6.37%
1 Year Return
+3.47%
3 Year Return
+181.12%
5 Year Return
+409%
10 Year Return
–
AUM
$3.92B
AUM Growth
+$3.92B
(+6%)
Cap. Flow
+$265M
Cap. Flow
% of AUM
6.75%
Top 10 Holdings %
Top 10 Hldgs %
36.15%
Holding
133
New
20
Increased
42
Reduced
20
Closed
29
Top Buys
| 1 |
Regeneron Pharmaceuticals
REGN
|
$92.2M |
| 2 |
AstraZeneca
AZN
|
$84.8M |
| 3 |
Baxter International
BAX
|
$69.3M |
| 4 |
Stevanato
STVN
|
$64.3M |
| 5 |
Caribou Biosciences
CRBU
|
$59.1M |
Top Sells
| 1 |
Maravai LifeSciences
MRVI
|
$124M |
| 2 |
Medtronic
MDT
|
$66.4M |
| 3 |
Biogen
BIIB
|
$63.7M |
| 4 |
NeoGenomics
NEO
|
$61.7M |
| 5 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$55.7M |
Sector Composition
| 1 | Healthcare | 97.34% |
| 2 | Technology | 1.13% |
| 3 | Financials | 0.61% |
| 4 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $188M | 4.16% | 1,062,400 +309,400 | +41% | +$54.7M |
|
2
Arvinas
ARVN
$568M
| $184M | 4.07% | 2,234,700 +380,700 | +21% | +$31.3M |
|
3
AbbVie
ABBV
$372B
| $174M | 3.86% | 1,613,200 +128,800 | +9% | +$13.9M |
|
4
Vertex Pharmaceuticals
VRTX
$100B
| $168M | 3.72% | 926,400 -23,600 | -2% | -$4.28M |
|
5
Zentalis Pharmaceuticals
ZNTL
$122M
| $166M | 3.68% | 2,493,800 +333,800 | +15% | +$22.2M |
|
6
Avantor
AVTR
$9.18B
| $133M | 2.94% | 3,247,700 +67,700 | +2% | +$2.77M |
|
|
BHVN
7
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $130M | 2.88% | 934,200 +51,700 | +6% | +$7.18M |
|
8
Syndax Pharmaceuticals
SNDX
$1.41B
| $92.2M | 2.04% | 4,823,400 +208,400 | +5% | +$3.98M |
|
|
9
Regeneron Pharmaceuticals
REGN
$61.5B
| $92.2M | 2.04% | +152,300 | New | +$92.2M |
|
|
SGEN
10
DELISTED
Seagen Inc. Common Stock
SGEN
| $91.2M | 2.02% | 537,000 -103,000 | -16% | -$17.5M |
|
|
HZNP
11
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $90.5M | 2% | 826,000 +258,000 | +45% | +$28.3M |
|
|
BPMC
12
DELISTED
Blueprint Medicines
BPMC
| $85.5M | 1.9% | 832,000 +268,800 | +48% | +$27.6M |
|
|
13
AstraZeneca
AZN
$248B
| $84.8M | 1.88% | +1,412,000 | New | +$84.8M |
|
14
Neurocrine Biosciences
NBIX
$13.8B
| $81.4M | 1.8% | 848,900 +167,900 | +25% | +$16.1M |
|
15
Alnylam Pharmaceuticals
ALNY
$58.5B
| $80.6M | 1.79% | 427,000 +232,000 | +119% | +$43.8M |
|
16
Eli Lilly
LLY
$657B
| $76.2M | 1.69% | 330,000 -235,500 | -42% | -$54.4M |
|
17
Nuvation Bio
NUVB
$1.02B
| $72.2M | 1.6% | 7,263,488 +297,112 | +4% | +$2.95M |
|
18
Natera
NTRA
$23.1B
| $71.2M | 1.58% | 638,700 +202,700 | +46% | +$22.6M |
|
19
Hologic
HOLX
$14.9B
| $69.8M | 1.55% | 945,400 -263,400 | -22% | -$19.4M |
|
|
20
Baxter International
BAX
$12.7B
| $69.3M | 1.54% | +862,000 | New | +$69.3M |
|
|
ARNA
21
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $67.8M | 1.5% | 1,139,000 +196,000 | +21% | +$11.7M |
|
|
ISEE
22
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $66.6M | 1.48% | 4,100,000 +2,699,990 | +193% | +$43.8M |
|
23
United Therapeutics
UTHR
$13.8B
| $64.8M | 1.44% | 351,000 +114,600 | +48% | +$21.2M |
|
|
24
Stevanato
STVN
$6.28B
| $64.3M | 1.43% | +2,541,893 | New | +$64.3M |
|
25
Sotera Health
SHC
$4.65B
| $62.2M | 1.38% | 2,378,000 +468,000 | +25% | +$12.2M |
|